<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
         xmlns:dc="http://purl.org/dc/terms/"
         xmlns:foaf="http://xmlns.com/foaf/0.1/"
         xmlns:bibo="http://purl.org/ontology/bibo/"
         xmlns:fabio="http://purl.org/spar/fabio/"
         xmlns:owl="http://www.w3.org/2002/07/owl#"
         xmlns:event="http://purl.org/NET/c4dm/event.owl#"
         xmlns:ore="http://www.openarchives.org/ore/terms/">

    <rdf:Description rdf:about="https://ris.uni-paderborn.de/record/54942">
        <ore:isDescribedBy rdf:resource="https://ris.uni-paderborn.de/record/54942"/>
        <dc:title>Functional Characterization of a Partial Loss-of-Function Mutation of the Epithelial Sodium Channel (ENaC) Associated with Atypical Cystic Fibrosis</dc:title>
        <bibo:authorList rdf:parseType="Collection">
            <foaf:Person>
                <foaf:name></foaf:name>
                <foaf:surname></foaf:surname>
                <foaf:givenname></foaf:givenname>
            </foaf:Person>
            <foaf:Person>
                <foaf:name></foaf:name>
                <foaf:surname></foaf:surname>
                <foaf:givenname></foaf:givenname>
            </foaf:Person>
            <foaf:Person>
                <foaf:name></foaf:name>
                <foaf:surname></foaf:surname>
                <foaf:givenname></foaf:givenname>
            </foaf:Person>
            <foaf:Person>
                <foaf:name></foaf:name>
                <foaf:surname></foaf:surname>
                <foaf:givenname></foaf:givenname>
            </foaf:Person>
            <foaf:Person>
                <foaf:name></foaf:name>
                <foaf:surname></foaf:surname>
                <foaf:givenname></foaf:givenname>
            </foaf:Person>
            <foaf:Person>
                <foaf:name></foaf:name>
                <foaf:surname></foaf:surname>
                <foaf:givenname></foaf:givenname>
            </foaf:Person>
            <foaf:Person>
                <foaf:name></foaf:name>
                <foaf:surname></foaf:surname>
                <foaf:givenname></foaf:givenname>
            </foaf:Person>
            <foaf:Person>
                <foaf:name></foaf:name>
                <foaf:surname></foaf:surname>
                <foaf:givenname></foaf:givenname>
            </foaf:Person>
            <foaf:Person>
                <foaf:name></foaf:name>
                <foaf:surname></foaf:surname>
                <foaf:givenname></foaf:givenname>
            </foaf:Person>
            <foaf:Person>
                <foaf:name></foaf:name>
                <foaf:surname></foaf:surname>
                <foaf:givenname></foaf:givenname>
            </foaf:Person>
            <foaf:Person>
                <foaf:name></foaf:name>
                <foaf:surname></foaf:surname>
                <foaf:givenname></foaf:givenname>
            </foaf:Person>
            <foaf:Person>
                <foaf:name></foaf:name>
                <foaf:surname></foaf:surname>
                <foaf:givenname></foaf:givenname>
            </foaf:Person>
        </bibo:authorList>
        <bibo:abstract>Loss-of-function mutations of the epithelial sodium channel (ENaC) may contribute to pulmonary symptoms resembling those of patients with atypical cystic fibrosis (CF). Recently, we identified a loss-of-function mutation in the alpha-subunit of ENaC (alphaF61L) in an atypical CF patient without mutations in CFTR. To investigate the functional effect of this mutation, we expressed human wild-type alpha beta gamma-ENaC or mutant alpha(F61L) beta gamma-ENaC in Xenopus laevis oocytes. The alphaF61L mutation reduced the ENaC mediated whole-cell currents by approximately 90%. In contrast, the mutation decreased channel surface expression only by approximately 40% and did not alter the single-channel conductance. These findings indicate that the major effect of the mutation is a reduction of the average channel open probability (P(o)). This was confirmed by experiments using the betaS520C mutant ENaC which can be converted to a channel with a P(o) of nearly one, and by experiments using chymotrypsin to proteolytically activate the channel. These experiments revealed that the mutation reduced the average P(o) of ENaC by approximately 75%. Na(+) self inhibition of the mutant channel was significantly enhanced, but the observed effect was too small to account for the large reduction in average channel P(o). The ENaC-activator S3969 partially rescued the loss-of-function phenotype of the alphaF61L mutation. We conclude that the alphaF61L mutation may contribute to respiratory symptoms in atypical CF patients.</bibo:abstract>
        <bibo:volume>25</bibo:volume>
        <bibo:issue>001</bibo:issue>
        <bibo:startPage>145–158</bibo:startPage>
        <bibo:endPage>145–158</bibo:endPage>
        <dc:publisher>S. Karger AG</dc:publisher>
        <bibo:doi rdf:resource="10.1159/000272059" />
        <ore:similarTo rdf:resource="info:doi/10.1159/000272059"/>
    </rdf:Description>
</rdf:RDF>
